Search This Website


NTAGI chief's opinion on widening gap in Kovishield

NTAGI chief's opinion on widening gap in Kovishield :Dr. Arora gave the example of England, saying- the result was 88% good; Decision taken on scientific basis

According to data from England, the 12-week gap has improved vaccination results from 65% to 88%.

In the matter of increasing the gap between the first and second doses of the vaccine, Dr. of the National Technical Advisory Group of Immunization (NTAGI). NK Arora's statement has come. Dr. Citing the example of England, Arora said the government had justified the decision.

also read 

Southern Railway Recruitment 2021 Notification|Apply Online Apprentice 3322 Posts

He said the UK's data showed that vaccination results ranged from 65 per cent to 88 per cent, with a gap of 12 weeks. There he benefited a lot. Due to this the vaccination gap in India was widened to 12 to 16 weeks. Dr. Arora said the decision was made on a scientific basis.

According to the data transfer
NTAGI chief further said that our group has taken this decision collectively. A transparent system was adopted for this. It is constantly coming to light that the data is being modified. The earlier 4 to 6 week gap was also decided based on the data available at the time. A second dose between 4 and 6 weeks yields 57 to 60 percent results.


BEST MAGICIANS Around The World | Magician's Got Talent

Decision to reduce the gap After research,
Dr. Arora said that the decision to reduce the gap in the next 2 doses of Kovishield will be made after research. A decision will be made if it is further proven that there is a benefit to be gained from the gap. If there is a good result on the gap that has been fixed, it will be taken forward.

Speaking on the UK model, the NTAGI chief said that 33 per cent of the results have come out after the first dose of AstraZeneca and 60 per cent after the second dose. Only then was it considered to widen its gap there. However, it is being tracked in India. It will tell you how much you are benefiting from it.

How many people will need a second dose of Kovishield in 28-42 days?
This is the third change in the two-dose gap of Covishield. The two-dose gap between Covishield and Covacin was kept at 28-42 days if vaccination started on 16 January. But on March 22, the two-dose interval between Covishield was increased from 4-6 weeks to 6-8 weeks. Then on March 13 this gap was widened to 12-16 weeks.

also read 

All Part Ramayan watch Online

The new guideline is for people who have already taken the first dose and are traveling internationally. They may have to travel, study, work or be part of an Olympic team. People will not have to wait 84 days for a second dose of Covishield. They may take a second dose before this.


Desperate CCTV:Father-son crushed as tractor-trolley full of sand falls, dies on turn

The second dose was given to
the foreigner 28 days later. Earlier, the Ministry of Health had changed the vaccination schedule of Kovishield. After widening the second dose gap a second time it was now reduced for those going on overseas travel. In some categories there is no need to wait 84 days (12-16 weeks) for two doses. A second dose can be given after 28 days (4-6) weeks. The two-dose gap was reduced to covishield only. The gap between the 2 doses of covacin was 28 days. No changes were made.

Read in Gujarati news 

Why was this change made in the dosing police of Kovishield?
This change has been made in the Standard Operating Procedures (SOPs) issued for people traveling outside India. Kovishield has been jointly developed by Oxford University and the British company AstraZeneca. It has been approved by the World Health Organization (WHO). It is safe to travel outside India after taking two doses. They will also have a lower risk of infection. At the same time, they will be protected from new booming mutants.

This policy does not apply to all. If a person has to go abroad within 84 days, a second dose may be given. Others may not get this relief. He will have to wait 84 days to take the second dose.

No comments:

Post a Comment